Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx

Abstract

This phase I study assessed the safety of first-in-class radioenhancer nanoparticles, NBTXR3, in elderly or frail patients with locally advanced head and neck squamous cell carcinoma (HNSCC), ineligible for chemoradiation.

Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [18F]FMISO PET/CT

“…In this study, the concept of DE to hypoxic subvolumes in HNC was tested. Other studies currently investigate alternative strategies to improve LC in HNC, such as [89]Zr-Cetuximab [35], FDG-PET based dose painting [30,31,36], DE via radioenhancer nanoparticles [37], or functional MRI guided photon or proton DE [38]. With the growing availability of magnetic resonance imaging (MRI), this modality may provide attractive and pragmatic functional imaging biomarkers which might in the future replace more complicated methods like dynFMISO PET/CT for detecting radioresistant, hypoxic sub-volumes [39,40].…”

Imaging Features of Intratumoral Injection of NBTXR3 for Head and Neck Squamous Cell Carcinoma Lymph Node Metastases

“…The material appears as markedly hyperattenuating deposits without significant beam-hardening artifact, which facilitates delineating the dispersion (coverage of the tumor volume) of the injected material. The hyperattenuating appearance is attributable to the hafnium oxide component, which has the desirable property of high X-ray attenuation for treatment purposes as a radioenhancer [ 1 ]. This property is also useful for verifying the dispersion of the material with respect to the target tumor.…”

“…The nanoparticles augment the absorption of ionizing radiation, resulting in increased tumor cell death. Intratumoral injection of NBTXR3 followed by radiation therapy has been found to be feasible and safe for a variety of tumors, such as locally advanced squamous cell carcinoma of the oral cavity or oropharynx and soft tissue sarcomas [ 1 , 2 , 3 ]. However, there is a paucity of reports describing the imaging findings of NBTXR3 injection for the treatment of patients with head and neck squamous cell carcinomas.…”

Multifunctional high-Znanoradiosensitizers for multimodal synergistic cancer therapy

“…64,65 To date, a series of clinical trials on NBTXR3 for different tumors have been conducted, such as head and neck cancer, which are expected to be in wider clinical use in the future. 66 However, NBTXR3 was administered by intratumoral injection in the treatment of locally advanced soft-tissue sarcoma, limiting its further application. Li et al synthesized large-scale and intravenously injectable HfO 2based nanocrystals for breast cancer RT.…”